A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Sponsor
Beijing Chest Hospital
Study ID
NCT04950400
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Carrelizumab + chemotherapy + apatinib — DRUG
    Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.

Study Details

The purpose of the study is to evaluate the safety and efficacy of camrelizumab combined with chemotherapy in the first-line treatment of advanced in NSCLC patients.

Key Dates

Start date
Jul 7, 2021
Status verified
Jun 2021
Primary completion
Dec 12, 2023
Completion
Apr 4, 2024

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Carrelizumab + chemotherapy + apatinib

Primary Outcome Measure

Progression-free survival [ Time Frame: 1 Year ]

Central Contacts

Related Studies